Neuroscientific Biopharmaceuticals Ltd
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated … Read more
Neuroscientific Biopharmaceuticals Ltd (NSB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.029x
Based on the latest financial reports, Neuroscientific Biopharmaceuticals Ltd (NSB) has a cash flow conversion efficiency ratio of -0.029x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-480.55K) by net assets (AU$16.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Neuroscientific Biopharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Neuroscientific Biopharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Neuroscientific Biopharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuroscientific Biopharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MGB Bhd
KLSE:7595
|
-0.059x |
|
Hilan Ltd
TA:HLAN
|
0.096x |
|
Whetron Electronics Co.,Ltd.
TWO:6722
|
0.088x |
|
MegaMD Co. Ltd
KQ:133750
|
0.038x |
|
Omiris AG
F:HBD1
|
N/A |
|
The Ruby Mills Limited
NSE:RUBYMILLS
|
-0.051x |
|
Trimitra Prawara Goldland Tbk Pt
JK:ATAP
|
0.014x |
|
Precise Biometrics AB (publ)
PINK:PRBCF
|
0.015x |
Annual Cash Flow Conversion Efficiency for Neuroscientific Biopharmaceuticals Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Neuroscientific Biopharmaceuticals Ltd from 2016 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$16.81 Million | AU$-941.33K | -0.056x | -776.94% |
| 2024-06-30 | AU$5.35 Million | AU$44.25K | 0.008x | +101.68% |
| 2023-06-30 | AU$4.69 Million | AU$-2.30 Million | -0.491x | +60.97% |
| 2022-06-30 | AU$5.52 Million | AU$-6.94 Million | -1.258x | -606.05% |
| 2021-06-30 | AU$14.60 Million | AU$-2.60 Million | -0.178x | +71.50% |
| 2020-06-30 | AU$3.65 Million | AU$-2.28 Million | -0.625x | -124.79% |
| 2019-06-30 | AU$5.06 Million | AU$-1.41 Million | -0.278x | +59.09% |
| 2018-06-30 | AU$732.52K | AU$-497.91K | -0.680x | -95.36% |
| 2017-06-30 | AU$535.79K | AU$-186.42K | -0.348x | +50.65% |
| 2016-06-30 | AU$124.47K | AU$-87.76K | -0.705x | -- |